Lexicon Pharmaceuticals (LXRX) Gross Margin (2016 - 2026)

Lexicon Pharmaceuticals (LXRX) has 10 years of Gross Margin data on file, last reported at 99.49% in Q1 2026.

• Gross Margin for Q1 2026 came in at 99.49%, up 187.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 99.49% (up 146.0% YoY), and the FY2025 annual result was 99.45%, up 143.0% from the prior year.
• Gross Margin rose to 99.49% in Q1 2026 per LXRX's latest filing, from 96.34% in the prior quarter.
• Over five years, Gross Margin peaked at 99.93% in Q3 2025 and troughed at 89.92% in Q2 2024.
• A 4-year average of 96.58% and a median of 97.32% in 2024 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2024 and 2025: Gross Margin sank 756 bps in 2024, then soared 996 bps in 2025.
• A 4-year view of Gross Margin shows it stood at 90.86% in 2023, then advanced by 9 bps to 98.69% in 2024, then fell by 2 bps to 96.34% in 2025, then grew by 3 bps to 99.49% in 2026.
• Business Quant data shows LXRX's Gross Margin at 99.49% in Q1 2026, 96.34% in Q4 2025, and 99.93% in Q3 2025.